My Account
Amgen
SYMBOL:AMGN|SECTOR:Health Care|DERIVED:CFD
Derived prices are not provided by exchanges. They are derived by market makers in CFD OTC market and hence prices may not be accurate and may differ from the actual market price, meaning prices are indicative only and not appropriate for trading purposes. Therefore Moneycontrol doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
$35682
3
5
.
6
8
2
2.63 (0.93%)
As on 28 Dec, 2023 | 02:29 IST
Day Range
283.35
287.29
LH
52 Week Range
211.71
288.46
LH
| Open | 284.50 |
| Previous Close | 283.90 |
| Beta | -0.07 |
| High | 287.29 |
| Low | 283.35 |
| TTM EPS See historical trend | 17.42(+3.39% YoY) |
| 52 Week High | 288.46 |
| 52 Week Low | 211.71 |
| TTM PE See historical trend | 16.45(High PE) |
| Mkt. Cap ($ Billion) | 153.36 |
| Dividend Yield | 3.52 |
Advanced Chart
*Delayed by 20 seconds.
MC Technicals
Moving Averages
| Days | |
|---|---|
| 5 | 281.83 |
| 10 | 279.58 |
| 20 | 275.18 |
| 50 | 271.63 |
| 100 | 267.8 |
| 200 | 249.98 |
Returns
Price Performance
| 1 Week | 4.14% | |
| 1 Month | 8.43% | |
| 3 Months | 6.54% | |
| YTD | 9.14% | |
| 1 Year | 8.80% | |
| 3 Years | 28.54% |
Financialsin million $
Peers
| Name | Price ($) | Change% | M.Cap(Billion $) | TTM PE | TTM EPS | DY | 52 wk high/low | Technical Rating | |
|---|---|---|---|---|---|---|---|---|---|
| Eli Lilly | 580.96 | 1.80 | 552.18 | 71.90 | 8.09 | 1.21 | 629.97/302.14 | -1.77 | Neutral |
| J&J | 156.24 | 0.06 | 376.47 | 15.38 | 10.17 | 2.92 | 180.93/144.95 | 3.33 | Bullish |
| Merck | 107.84 | 0.20 | 273.65 | 14.44 | 7.48 | 3.20 | 119.65/96.36 | 6.56 | Very Bullish |
| AbbVie | 154.88 | 0.17 | 273.57 | 13.00 | 11.92 | 4.39 | 168.11/130.96 | 11.40 | Very Bullish |
| Pfizer | 28.62 | 0.74 | 161.60 | 4.32 | 6.63 | 3.66 | 51.67/25.76 | -4.95 | Bearish |
Market news
- Wall Street ends higher in final stretch of 2023, rate cuts in viewDecember 27, 2023 6:03 AM
- S&P 500 ends higher ahead of long holiday weekendDecember 23, 2023 9:12 AM
- JIM Standalone September 2023 Net Sales at Rs 1.01 crore, up 30.91% Y-o-YDecember 22, 2023 12:18 PM
- Wall Street ends higher, extending rate-cut rallyDecember 19, 2023 5:57 AM
About the company
Amgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes ENBREL, Prolia (denosumab), Neulasta (pegfilgrastim), Otezla, XGEVA, Aranesp (darbepoetin alfa), KYPROLIS, Repatha (evolocumab), Nplate (romiplostim), Vectibix (panitumumab), MVASI (bevacizumab-awwb), Parsabiv (etelcalcetide), EPOGEN (epoetin alfa), KANJINTI (trastuzumab-anns), BLINCYTO (blinatumomab), Aimovig (erenumab-aooe), EVENITY (romosozumab-aqqg), AMGEVITATM (adalimumab), Sensipar/Mimpara (cinacalcet), NEUPOGEN (filgrastim), IMLYGIC (talimogene laherparepvec), Corlanor (ivabradine) and AVSOLA (infliximab-axxq). It focuses on human therapeutics for the treatment of serious illness in the areas of inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology and neuroscience.